State Street SPDR S&P Pharmaceuticals ETF

XPH

Market cap $204M

The US has agreed to spare the UK from threatened trade tariffs on pharmaceutical products.

Agreement also calls for NHS to increase net price it pays for new medicines by 25%

Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.

The UK is poised to agree on a major pharmaceuticals deal with the U.S., which will mean zero import tariffs on pharmaceutical products into the U.S. and lead to an increase in NHS spending on medicines, The Times reported on Monday.

Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

SPDR S&P Pharmaceuticals ETF is rated a "Buy" due to compelling valuation and improving technical momentum. XPH offers diversified exposure to large-, mid-, and small-cap pharma stocks, balancing blue-chip stalwarts and speculative biotech. The ETF's price-to-earnings ratio is under 10, and recent share-price momentum has improved, though risk remains due to industry concentration.

The administration has been weighing duties for months on a range of products and ingredients in a national-security tariff investigation.